Evaxion (ADR) (EVAX)
Decodes immune biology with AI to build vaccine candidates and partner programs.
Something off on this page? Send us feedback.
Develops vaccine candidates for cancer and infectious diseases through its AI-Immunology platform. The model combines a clinical pipeline with partnership-driven target discovery, drug design, and development.
Built around AI-Immunology™, the platform decodes the human immune system to identify vaccine targets for cancer and infectious diseases. Multidisciplinary capabilities extend from target discovery through early clinical development, pairing computational discovery with wet-lab and animal validation. The platform is also planned to expand into autoimmune diseases.
Revenue opportunities are pursued through both the platform and clinical pipeline rather than a candidate-only model, including multi-partner agreements for vaccine target discovery, drug design, and development. The US-market listing uses Nasdaq-traded ADSs, and continued access depends on meeting Nasdaq requirements on an ongoing basis.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Mar 9, 2026 | Lake Street | Reiterate | Buy | $11 | $9 |
| Feb 19, 2026 | Maxim Group | Target | $10 | ||
| Oct 20, 2025 | Lake Street | Reiterate | Buy | $11 | |
| Sep 25, 2025 | H.C. Wainwright | Target | $16 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $14.0M · Total debt $7.1M · Total assets $19.4M · Shareholders' equity $9.5M
- Revenue
- $0
- Operating income
- −$3.8M
- Net income
- −$3.7M
No dividends on record.
| Institutions15 holders · as of Mar 31, 2026 | 5.20% | 328.6K ADS | |
| Insiders10 holders · as of Apr 24, 2026 | 4.58% | 289.2K ADS | |
| Otherremainder | 90.22% | 5.70M ADS |
6.32M ADS (1 ADS = 50 ordinary shares) as of Sep 1, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (8.34M in the company's Sep 3, 2026 report, 6.32M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Andreas Holm MattssonInsiderofficer: CAIO Chief AI Officer | 1.75% | 5.52M ordinary | Form 4filed Apr 10, 2026 ↗ |
Ikarian Capital, LLCInstitution | 1.18% | 74,698 ADS | 13Fas of Mar 31, 2026 |
Marianne SoegaardInsiderdirector | 1.14% | 3.60M ordinary | Form 4filed Apr 2, 2026 ↗ |
Rathbones Group PLCInstitution | 0.72% | 45,723 ADS | 13Fas of Mar 31, 2026 |
Helen Katrina Tayton-MartinInsiderofficer: Chief Executive Officer | 0.72% | 2.29M ordinary | Form 4filed Mar 31, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
Nothing filed in the last 12 months.
- BioNTech (ADR)
Individualized cancer vaccines plus bacterial and viral vaccines
- Moderna
Personalized cancer vaccines and viral-vaccine platforms
- GSK (ADR)
Prophylactic bacterial and viral vaccine programs
- Pfizer
Prophylactic bacterial vaccines and vaccine development
- Sanofi (ADR)
Prophylactic bacterial and viral vaccine programs
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Evaxion (ADR) | $3.00 | −3.07% | $19.4M | — | — | 2.6 | +148.3% |
| BioNTech (ADR) | $104.42 | +0.63% | $26.08B | — | — | 8.5 | −60.7% |
| Moderna | $147.42 | −2.26% | $59.84B | — | — | 26.9 | +2.1% |
| GSK (ADR) | $50.57 | +0.29% | $101.06B | 15.8 | 9.1 | 2.2 | +2.7% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Sanofi (ADR) | $44.54 | +0.17% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Median | 38.3 | 9.8 | 2.6 | +2.6% |